{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-093983","form_type":"8-K/A","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.916918+00:00","generated_at":"2026-05-17T05:15:08.345926+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CorMedix files Melinta acquisition financials; Melinta 2024 revenue $120M, net loss $4.7M","bullets":["Melinta 2024 total revenue $119.97M (product $106.3M) vs $105.6M in 2023; net loss narrowed to $4.7M from $36.0M.","Cash and equivalents $49.8M at Dec 31, 2024; total assets $177.6M, notes payable $84.9M.","CorMedix acquired Melinta on Aug 29, 2025 for undisclosed terms; Melinta markets seven anti-infective brands including BAXDELA, VABOMERE, ORBACTIV."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-093983","json":"https://secwatch.observer/filing/0001213900-25-093983.json","markdown":"https://secwatch.observer/filing/0001213900-25-093983.md","text":"https://secwatch.observer/filing/0001213900-25-093983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025093983/0001213900-25-093983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025093983/ea0258874-8ka1_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:15:08.345926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}